# Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

> **NCT00750841** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 64 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** cediranib

## Key facts

- **NCT ID:** NCT00750841
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2008-09-09
- **Primary completion:** 2009-07-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00750841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00750841, "Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00750841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*